Outpatient parenteral antimicrobial therapy (OPAT) using a continuous ambulatory delivery device (CADD) allowing treatment with multiple daily doses: a brief report of a Norwegian experience.

Autor:	Skogen V; Department of Clinical Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, PO Box 6050 Langnes, Tromsø N-9037, Norway.; Department of Infectious Diseases, Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway., Helleren R; Department of Internal Medicine, Sørlandet Hospital, Kristiansand, Norway., Jacobsen MG; Department of Internal Medicine, Sørlandet Hospital, Kristiansand, Norway., Opsal A; Department of Health and Nursing Science, University of Agder, Kristiansand, Norway.; Department of Clinical Research, Sørlandet Hospital, Kristiansand, Norway., Gallefoss F; Department of Clinical Research, Sørlandet Hospital, Kristiansand, Norway.; Faculty of Medicine, University of Bergen, Bergen, Norway.
Jazyk:	angličtina
Zdroj:	JAC-antimicrobial resistance [JAC Antimicrob Resist] 2024 Oct 14; Vol. 6 (5), pp. dlae155. Date of Electronic Publication: 2024 Oct 14 (Print Publication: 2024).
DOI:	10.1093/jacamr/dlae155
Abstrakt:	Background: Outpatient parenteral antimicrobial therapy (OPAT) is safe, effective and increasingly available. While OPAT in Norwegian healthcare has been rare, a new continuous ambulatory delivery device (CADD) allowing multiple daily dosing treatments has been innovated making OPAT more accessible. Objectives: To describe the clinical outcome and safety using CADD in an OPAT setting. Methods: Adult patients in need of parenteral antibiotic treatment were offered OPAT and discharged with a programmable digital infusion pump allowing multiple daily dosings. Results: Altogether, 170 patients were included in the study, among which 21% of all patients (36 of 170) were readmitted to hospital while receiving OPAT or within 30 days after end of intravenous antibiotics. None of the 170 patients died due to OPAT and allergies were not noticeable as a problem. Conclusions: We have developed a safe and clinically effective programme offering OPAT in accordance with Norwegian antibiotic treatment guidelines. (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu